Avaliação da atividade antiviral de peptídeos sintéticos contra o herpes vírus humano 1 e o aichivírus

• Ano de defesa: 2014
• Autor(a) principal: Vilas Boas, Liana Costa Pereira
• Orientador(a): Franco, Octávio Luiz
• Tipo de documento: Dissertação
• Tipo de acesso: Acesso aberto
• Idioma: por
• Instituição de defesa: Universidade Católica de Brasília
• Programa de Pós-Graduação: Programa Strictu Sensu em Ciências Genômicas e Biotecnologia
• Departamento: Escola de Saúde e Medicina
• País: Brasil
• Palavras-chave em Português: Agentes antivirais; Vírus do herpes; Peptídeos
• Área do conhecimento CNPq: CIENCIAS BIOLOGICAS::GENETICA
• Link de acesso: https://bdtd.ucb.br:8443/jspui/handle/tede/2139

Viral infections affect every living organism. Health care programs and vaccines have been developed to control and prevent those infections, but there is still the occurrence of severe diseases and with great social-economic importance, whose only alternative is the treatment with antivirals drugs. Those compounds possess different mechanisms of action and are specific for each virus. Nevertheless, with many viruses resistant strains rise, a growing interest in novel antivirals development or in the improvement of existing drugs have been observed. In the last few years, antimicrobial peptides have shown antiviral activities making them candidates for antiviral drugs. The present study aimed to evaluate the possible antiviral activities of synthetic peptides clavanin MO, LL-37, Cn-AMP1 and variants of the Pa-MAP1 against HSV-1 and the Aichivirus replication. The peptides cytotoxic effects against Vero cells were evaluated by MTT method, whereas the clavanin MO, the Pa-MAP 1.8 and Pa-MAP 18br showed more cytotoxicity, with concentrations higher than 15,4 µM and 12 µM, respectively. Considering the antivirals assays, it was observed that the peptide Pa-MAP 1 causes 90 % of HSV-1 replication, with a SI higher than 4.8 and a virucidal mechanism of action, but null against the Aichivirus. Futhermore LL- 37 presented 90 % of Aichivirus inhibition, with a SI of 3.4. Others peptides tested showed percentages below 41 %. Future studies are need in order to elucidate which HSV-1 structure does Pa-MAP1 interacts and futher extend to in vivo tests. In summary, this study it is the first one to describe antiviral tests for the treatment of the Aichivirus infection.